Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marion Subklewe

Showing results (191-200 of 244) with videos related to

Pageof 25
Sort By:
Blood Advances|March 10, 2022
Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphomaGloria Iacoboni, Kai Rejeski, Guillermo Villacampa, et al.
Neurology|March 17, 2026
Clinical Manifestations of Primary CNS T-Cell Lymphoma: A Retrospective Study of Histopathologic, Molecular, and Neuroimaging FeaturesKatharina Johanna Müller, Philipp Karschnia, Leon D Kaulen, et al.
Blood Advances|September 25, 2023
Early quantification of anti-CD19 CAR T cells by flow cytometry predicts response in R/R DLBCLViktoria Blumenberg, Galina Busch, Stephan Baumann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 24, 2023
Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell TherapyGloria Iacoboni, Víctor Navarro, Ana África Martín-López, et al.
Leukemia|March 24, 2020
Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 studyPau Montesinos, Gail J Roboz, Claude-Eric Bulabois, et al.
Blood|May 13, 2025
Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatmentRichard Pelzl, Giulia Benintende, Franziska Gsottberger, et al.
Oncoimmunology|January 23, 2023
<i>In vivo</i> dynamics and anti-tumor effects of EpCAM-directed CAR T-cells against brain metastases from lung cancerTao Xu, Philipp Karschnia, Bruno Loureiro Cadilha, et al.
Blood|June 24, 2021
CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphomaKai Rejeski, Ariel Perez, Pierre Sesques, et al.
Hemasphere|October 29, 2025
Operational burden and fragmented implementation in CAR T-cell therapy: Insights from a multinational survey by the GoCART Coalition and the JACIE Quality Managers CommitteeNick van Sinderen, Julie Dolva, Caterina Riillo, et al.
Cell Death and Differentiation|January 22, 2025
ARID1A mutations protect follicular lymphoma from FAS-dependent immune surveillance by reducing RUNX3/ETS1-driven FAS-expressionMartina Antoniolli, Maria Solovey, Johannes Adrian Hildebrand, et al.
Pageof 25

Showing results (191-200 of 244) with videos related to

Sort By:
Pageof 25
Blood Advances|March 10, 2022
Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphomaGloria Iacoboni, Kai Rejeski, Guillermo Villacampa, et al.
Neurology|March 17, 2026
Clinical Manifestations of Primary CNS T-Cell Lymphoma: A Retrospective Study of Histopathologic, Molecular, and Neuroimaging FeaturesKatharina Johanna Müller, Philipp Karschnia, Leon D Kaulen, et al.
Blood Advances|September 25, 2023
Early quantification of anti-CD19 CAR T cells by flow cytometry predicts response in R/R DLBCLViktoria Blumenberg, Galina Busch, Stephan Baumann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 24, 2023
Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell TherapyGloria Iacoboni, Víctor Navarro, Ana África Martín-López, et al.
Leukemia|March 24, 2020
Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 studyPau Montesinos, Gail J Roboz, Claude-Eric Bulabois, et al.
Blood|May 13, 2025
Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatmentRichard Pelzl, Giulia Benintende, Franziska Gsottberger, et al.
Oncoimmunology|January 23, 2023
<i>In vivo</i> dynamics and anti-tumor effects of EpCAM-directed CAR T-cells against brain metastases from lung cancerTao Xu, Philipp Karschnia, Bruno Loureiro Cadilha, et al.
Blood|June 24, 2021
CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphomaKai Rejeski, Ariel Perez, Pierre Sesques, et al.
Hemasphere|October 29, 2025
Operational burden and fragmented implementation in CAR T-cell therapy: Insights from a multinational survey by the GoCART Coalition and the JACIE Quality Managers CommitteeNick van Sinderen, Julie Dolva, Caterina Riillo, et al.
Cell Death and Differentiation|January 22, 2025
ARID1A mutations protect follicular lymphoma from FAS-dependent immune surveillance by reducing RUNX3/ETS1-driven FAS-expressionMartina Antoniolli, Maria Solovey, Johannes Adrian Hildebrand, et al.
Pageof 25